Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatric AML patients show high expression of the CD123 antigen, and this finding provides the biological basis to target CD123 with the chimeric antigen receptor (CAR). However, CAR.CD123 therapy in AML is hampered by on-target off-tumour toxicity and a long "vein-to-vein" time.
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia / Caruso, Simona; De Angelis, Biagio; Del Bufalo, Francesca; Ciccone, Roselia; Donsante, Samantha; Volpe, Gabriele; Manni, Simona; Guercio, Marika; Pezzella, Michele; Iaffaldano, Laura; Silvestris, Domenico Alessandro; Sinibaldi, Matilde; Di Cecca, Stefano; Pitisci, Angela; Velardi, Enrico; Merli, Pietro; Algeri, Mattia; Lodi, Mariachiara; Paganelli, Valeria; Serafini, Marta; Riminucci, Mara; Locatelli, Franco; Quintarelli, Concetta. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - 15:1(2022), pp. 1-19. [10.1186/s13045-022-01376-3]
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Caruso, Simona;Donsante, Samantha;Manni, Simona;Guercio, Marika;Pezzella, Michele;Riminucci, Mara;
2022
Abstract
Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatric AML patients show high expression of the CD123 antigen, and this finding provides the biological basis to target CD123 with the chimeric antigen receptor (CAR). However, CAR.CD123 therapy in AML is hampered by on-target off-tumour toxicity and a long "vein-to-vein" time.| File | Dimensione | Formato | |
|---|---|---|---|
|
Caruso_Safe-and-efective_2022.pdf
accesso aperto
Note: Articolo rivista
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
4.44 MB
Formato
Adobe PDF
|
4.44 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
